San Carlos, CA, United States of America

Jing Zhang

This inventor holds 1 USPTO granted patent. Top assignee: Attovia Therapeutics, Inc.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jing Zhang. Retrieved from https://idiyas.com/inventor/jing-zhang-787ae7va

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jing Zhang - Innovator in Therapeutics

Introduction

Jing Zhang is a notable inventor based in San Carlos, CA (US). She has made significant contributions to the field of therapeutics, particularly through her innovative research and development efforts.

Latest Patents

Jing Zhang holds a patent for "IL31-BINDING POLYPEPTIDES AND USES THEREOF." This patent showcases her expertise in creating polypeptides that have potential applications in various therapeutic contexts.

Career Highlights

Jing Zhang is currently employed at Attovia Therapeutics, Inc., where she continues to advance her research in the field. Her work at Attovia Therapeutics reflects her commitment to developing innovative solutions that address critical health challenges.

Collaborations

Jing collaborates with talented professionals, including Ole Petter Veiby and Shyr Jiann Li. These partnerships enhance her research and contribute to the success of her projects.

Conclusion

Jing Zhang is a dedicated inventor whose work in therapeutics is paving the way for future innovations. Her contributions, particularly in the area of IL31-binding polypeptides, highlight her role as a key player in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…